Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy

SSS health analyst Evelyn Hogg is among the authors of an article in the Journal of Infectious Diseases that explores the long-term durability of positive outcomes when omitting nucleoside reverse transcriptase inhibitors (a class of antiretroviral drug) from HIV salvage therapy (i.e., therapy given when the standard treatment for a disease is no longer effective and treatment options are limited). The AIDS Clinical Trial Group (ACTG) interventional clinical trial A5241 (The Optimized Treatment That Includes or Omits NRTIs Trial: A Randomized Strategy Study for HIV-1-Infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen [OPTIONS]) looked at 96-week results to show that HIV-1 salvage therapy can safely omit these drugs without compromising the response as long as the new regimen has a cumulative activity of more than two active drugs.The study was sponsored by the Division of AIDS at the National Institute of Allergy and Infectious Diseasesand was conducted at clinical sites in the United States.

Read more about SSS research activities in our online publication SSS Update.